

2018 CQDM¹, Oncopole and the Canadian Cancer Society co-fund a \$1.5 million project to support the expansion and validation of early discoveries led by Professors Claude Perreault and Pierre Thibault, Principal Investigators at IRIC² and the academic co-founders of Epitopea. The two researchers are pioneers of a novel approach designed to identify tumor-specific, biologically relevant targets on the surface of cancer cells.

2021 CREATION OF EPI TOPEA

Building on seminal findings from the project, Epitopea was founded in 2021 with the support of IRICoR. Epitopea is an innovative company in the field of RNA-based immunotherapies, committed to developing accessible, off-the-shelf therapies across the cancer tumor landscape and autoimmunity. Its mission is to commercialize differentiated RNA-based immunotherapies that leverage a new class of tumor-specific antigens (TSAs), Cryptigens™.



2022 \$14 MILLION SEED ROUND



To accelerate the R&D of its cancer immunotherapy pipeline, Epitopea raised US\$14 million in a financing round led by a transatlantic syndicate of investors, including CTI Life Sciences Fund, Fonds de solidarité FTQ, Advent Life Sciences and Cambridge Innovation Capital.

1.funding made possible through a grant from the Government of Quebec
2.Institute for Research in Immunology and Cancer of the Université de Montréal.

2023 REINFORCED RECOGNITION THANKS TO ITS VICTORY AT SWEET BIOPHARMA DAY



At the third edition of the sweet biopharma day competition, organized by CQDM and BioQuébec, Epitopea was recognized as a “highly promising company,” receiving the competition’s top honors. This distinction strengthened the company’s reputation and increased its visibility, both within the Canadian biotechnology ecosystem and among international investors.



2024 LAUNCH OF A SECOND CQDM PROJECT

Building on the success and impact of their first project, Professors Perreault and Thibault launched a second collaborative initiative, made possible through additional funding of \$1.5 million provided by CQDM¹ and supplementary funding provided by Epitopea. This initiative aims to further validate CryptoMap™, Epitopea’s innovative immunopeptidomics platform designed to analyze the surface of cancer cells and identify novel tumor-specific antigens or targets. The objective of this project builds on the prior funding and is focused on further accelerating the discovery and development of RNA-based immunotherapies capable of treating subsets of genetically defined patient populations.

1. funding made possible through a grant from the Government of Quebec.



\$31 MILLION



In the fall of 2024, Epitopea raised US\$31 million in a pre-Series A financing round to advance the CryptoMap™ platform and accelerate its first off-the-shelf RNA-based immunotherapy toward the clinic. In addition to existing investors—CTI Life Sciences, Fonds de solidarité FTQ, Advent Life Sciences and Cambridge Innovation Capital—the round welcomed new partners, including adMare BioInnovations, Jonathan Milner and Investissement Québec.

PARTNERSHIP WITH GENEVANT SCIENCES

Epitopea also entered into a strategic licensing partnership with Genevant Sciences, securing non-exclusive access to its clinically de-risked lipid nanoparticle (LNP) portfolio to support the development of its first product.

2025-2026 LICENSE AND RESEARCH COLLABORATION AGREEMENT WITH MSD (MERCK)

Epitopea entered into a research collaboration and exclusive licensing agreement with MSD (Merck) to identify Cryptigen™ tumor-specific antigens (TSAs) in an undisclosed solid tumor. Through its proprietary CryptoMap™ platform, Epitopea will identify novel tumor targets capable of triggering an immune response. In return, the company will receive an upfront payment, the amount of which has not been disclosed, and will be eligible for additional milestone-based payments tied to the achievement of specific research objectives up to \$300 million per product.

EPI TOPEA PREPARES TO LAUNCH ITS FIRST PHASE 1 CLINICAL STUDY



Epitopea triggers its GMP development campaign in support of its first clinical program, which is being coordinated by a dedicated clinical team charged with leading this first-in -human phase 1 trial in HRP+ ovarian cancer. The company plans to initiate this clinical trial in the first half of 2026.